Identifying novel pathways at the interface of immunity and metabolism

Publications

Landos Omilancor (BT-11) & LANCL2 Publications

Date Title
. First-in-class topical therapeutic omilancor ameliorates disease severity and inflammation through activation of LANCL2 pathway in psoriasis.. (opens in a new tab) Sci Rep. vol. 11, no. 19827, .
BT-11 (omilancor), a first-in-class, topical therapeutic for psoriasis, ameliorates disease severity and inflammation through activation of LANCL2 pathway. (opens pdf document in a new tab) 2021 American Association of Immunologists (AAI) Annual Meeting. .
The Safety, Tolerability, and Pharmacokinetics Profile of BT-11, an Oral, Gut-Restricted Lanthionine Synthetase C-Like 2 Agonist Investigational New Drug for Inflammatory Bowel Disease: A Randomized, Double-Blind, Placebo-Controlled Phase I Clinical Trial. (opens in a new tab) Inflammatory Bowel Diseases. .
Validation of lanthionine synthetase C-like 2 (LANCL2) as a therapeutic target for systemic lupus erythematosus. (opens in a new tab) The Journal of Immunology. .
Oral Treatment with BT-11 Ameliorates Inflammatory Bowel Disease by Enhancing Regulatory T Cell Responses in the Gut. (opens in a new tab) The Journal of Immunology. .
Nonclinical Toxicology and Toxicokinetic Profile of an Oral Lanthionine Synthetase C-Like 2 (LANCL2) Agonist, BT-11. (opens in a new tab) International Journal of Toxicology. .
Tu1739 – Translation of Immunometabolic Mechanisms of Bt-11 to Humans with Crohn’s Disease. (opens in a new tab) AGA Journals. .
Activation of LANCL2 by BT-11 Ameliorates IBD by Supporting Regulatory T Cell Stability Through Immunometabolic Mechanisms. (opens in a new tab) Inflammatory Bowel Diseases. .
An N,N-Bis(benzimidazolylpicolinoyl)piperazine (BT-11): A Novel Lanthionine Synthetase C-Like 2-Based Therapeutic for Inflammatory Bowel Disease. (opens in a new tab) ACS Publications. .
Exploratory Studies With BT-11: A Proposed Orally Active Therapeutic for Crohn’s Disease. (opens in a new tab) International Journal of Toxicology. .
Mo1691 Lanthionine Synthetase C-Like Receptor 2 (LANCL2): A Novel Therapeutic Target for Inflammatory Bowel Disease. (opens in a new tab) AGA Journals . .

Landos NX-13 Publications

Landos LABP-69 Publications